All News

This year's top inflammation article highlighted the first FDA-approved treatment for patients with bronchiectasis.

Our top RSV content of 2025 included how nirsevimab and clesrovimab changed RSV prevention among younger patients, as well as the positive impact of RSV vaccination in older individuals.

Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on disease burden and dysphagia indicators.

The conference focused on how to improve eye care across the country, including new methods of treating dry eye and utilizing new technologies to catch myopia earlier.

Patients with DLBCL who were treated with R-CHOP and quickly relapsed or were refractory to therapy had poor outcomes on second-line therapy.

Interim GLOVe trial results show that the frontline combination of glofitamab, lenalidomide, and venetoclax induces rapid, deep, and predominantly MRD-negative remissions in high-risk mantle cell lymphoma with manageable toxicity.

Federal policy changes, the push for fair pricing, and growing competition in the drug pipeline were major topics at this year’s meeting.

Trump secures new pricing deals with 9 drugmakers, advancing his effort to align US drug costs with Europe and expand direct-to-consumer purchasing.

The approval was based on the pivotal phase 3 FIBRONEER-ILD trial, in which nerandomilast slowed lung function decline in PPF and had similar discontinuation rates to placebo.

A new study links immune markers and coping patterns to disease control in adolescents with chronic urticaria.

A nationwide Danish cohort study reports cardiovascular events up to 1 year after infection, comparable to that observed with influenza.

Genetics played a major role in predicting worsening LVEF, progressing to a dilated cardiomyopathy phenotype, and a combined end point of both.

This year's top ovarian cancer article highlighted gaps in physician knowledge of genetic testing that may affect patient care.

Influenza and COVID-19 are seeing an uptick in incidence as the winter months approach, making protecting vulnerable populations a high priority.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Top pieces from 2025 spanned outbreaks, an FDA drug approval, and the impact of NIH grant terminations.

New research reveals that quick sleep onset may lower hypertension risk, challenging traditional views on sleepiness and cardiovascular health.

The study suggests that adding a Bruton tyrosine kinase inhibitor (BTKi) to frontline chemoimmunotherapy in Richter transformation improved complete response rates and progression-free survival compared with chemoimmunotherapy alone, though overall survival benefits remained unclear.

The San Antonio Breast Cancer Symposium fosters collaboration among experts, enhancing research and treatment strategies for breast cancer's complex landscape.

Readers of AJMC gravitated to articles on technology, policy, and clinical workflows, reflecting the pursuit of improved quality and responsible spending.

With new treatments, environmental insights, and evolving views on comorbidity shaping patient care, this is the most-viewed psoriasis content of 2025.

Experts at SABCS highlighted the aggressive nature of breast cancer in young women, emphasizing tailored management and support strategies.

Experts advocate for a shift in CKD care towards prevention and maintaining kidney health, emphasizing lifestyle changes and early interventions.

The 2025 American Thoracic Society International Conference brought advancements in pulmonary medicine and highlighted the need for health equity reforms.

Zasocitinib met all primary and secondary end points, showing rapid PASI 75 responses and high rates of skin clearance vs placebo and apremilast.

The approval of subcutaneous amivantamab can offer a more accessible means of treatment for patients with non–small cell lung cancer (NSCLC).

The FDA approved subcutaneous amivantamab with recombinant human hyaluronidase for EGFR-mutated NSCLC based on the phase 3 PALOMA-3 trial.

Advancements in 2025 in non-Hodgkin lymphoma treatments focused on bringing CAR T-cell therapy and bispecific antibodies into the community setting.